U041 Markers of Risk, Not Pre-melanomas: Case-based Management of Dysplastic Nevi
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Despite recent evidence that suggests dysplastic nevi (DN) are not obligate precursors to melanoma but are markers of melanoma risk, management of dysplastic nevi remains controversial and variable across dermatologists. This session will use a case-based approach to review data-driven guidelines to walk through appropriate surgical and non-surgical management, ways to discuss the DN natural history and follow-up cadence with patient, and adjunct screening and detection tools. These cases represent practical, real-life scenarios and will be presented using an audience response system.
LEARNING OBJECTIVES
Treat dysplastic nevi of all grades using data-driven guidelines
Communicate the implications of a dysplastic nevus diagnosis effectively with a patient
Develop a follow-up management plan for a patient with dysplastic nevi
SCHEDULE
12:30 PM
Dysplastic nevi: what margins?
Suephy C Chen, MD, FAAD
12:45 PM
Shared Decision Making for Management of Dysplastic Nevi
Elizabeth Gates Berry, MD, FAAD
1:00 PM
Optimizing Management for Patients with Dysplastic Nevi
Caroline C. Kim, MD, FAAD
1:15 PM
Q&A
SPEAKERS
Elizabeth Gates Berry, MD, FAAD
Suephy C Chen, MD, FAAD
Caroline C. Kim, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Elizabeth Gates Berry, MD, FAAD
Orlucent – Investigator(Grants/Research Funding);
Suephy C Chen, MD, FAAD
Sanofi Aventis – Other(Patent royalties or other compensation for Intellectual Property Rights); Syneos Health – Other(Patent royalties or other compensation for Intellectual Property Rights);
Caroline C. Kim, MD, FAAD
No financial relationships exist with ineligible companies.